Evidence map›Paper›PMID 40688045›Full record

ArticleLeukemia research reports2025

Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP).

M Dargenio, C Buquicchio, D Pastore, L Aprile, L Ciuffreda, G Greco, M Delia, V Federico, M P Fina, D Seripa and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

M DargenioHematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.
C BuquicchioHematology Unit, Dimiccoli Hospital, Barletta, Italy.
D PastoreHematology Unit, A. Perrino Hospital, Brindisi, Italy.
L AprileHematology Unit, Department of Hematology-Oncology, Moscati Hospital, Taranto, Italy.
L CiuffredaHematology Unit, Azienda Ospedaliero Universitaria-Ospedali Riuniti, Foggia, Italy.
G GrecoHematology and Transplant Unit, Cardinal Panico Hospital, Tricase, Italy.
M DeliaDepartment of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Bari, Italy.
V FedericoHematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.
M P FinaHematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.
D SeripaHematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.
R MateraHematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.
G TarantiniHematology Unit, Dimiccoli Hospital, Barletta, Italy.
A MaggiHematology Unit, Department of Hematology-Oncology, Moscati Hospital, Taranto, Italy.
L MelilloHematology Unit, Azienda Ospedaliero Universitaria-Ospedali Riuniti, Foggia, Italy.
V PavoneHematology and Transplant Unit, Cardinal Panico Hospital, Tricase, Italy.
P MustoDepartment of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Bari, Italy.
G SpecchiaSchool of Medicine, University of Bari "Aldo Moro", Bari, Italy.
N Di RenzoHematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with "3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside clinical trials. Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25-75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.

Indexed as

Acute myeloid leukemiaAllo-HSCTEfficacyImmunotherapyMRD

Identifiers

PMID40688045
PMCPMC12271813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.